Longli Zhang and Yifeng Ke are contributed equally to this work
The current treatment approaches for Coats’ disease by intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab or conbercept) combined with laser therapy were evaluated for the efficacy during the treatment.
The medical records of 28 patients diagnosed with Coats’ disease followed by the treatment with intravitreal injection of anti-VEGF agents and laser therapies at Tianjin Medical University Eye Hospital and Hebei Eye Hospital during July 2012 and October 2017 were reviewed retrospectively. Clinical outcomes were recorded with a minimum follow-up of 6 months. The patients were divided into ranibizumab- and conbercept-treated groups, as well as based on age: pediatric and adult groups.
Twenty-eight patients were involved in this study. The average number of the injections was 2.82 ± 0.98. Laser photocoagulation was conducted in all patients, and the average number of lasers was 2.63 ± 0.74. The average follow-up period was 24.29 ± 9.85 months. Fourteen patients (50%) were stable, 12 (43%) patients were improved, and 2 patients (7%) showed recurred subretinal fluid and exudation. The final best corrected visual acuity (BCVA) increased markedly after intravitreal injection of ranibizumab or conbercept combined with laser therapy (p = 0.029, p = 0.009, respectively). The number of injections and lasers between conbercept and ranibizumab groups did not vary significantly (p = 0.160, p = 0.573, respectively). Nine patients (60%) in the ranibizumab-treated group and five (38%) in the conbercept-treated group reached a stable phase, and five (33%) and seven (54%) patients got the vision improved after treated with ranibizumab or conbercept, respectively. In pediatric and adult groups, the initial and final BCVA differed significantly (p = 0.03, p = 0.008, respectively). However, the injection number was remarkably different (p = 0.02), while the laser numbers did not have any markedly difference (p = 0.38).
Intravitreal injection of ranibizumab or conbercept combined with laser therapy is an effective therapeutic option in Coats’ disease. Moreover, the intravitreal injection of ranibizumab or conbercept had no significant adverse effects and appeared to offer visual improvement in Coats’ disease.
Shienbaum G, Tasman WS (2006) Coats’ disease: a lifetime disease. Retina 26(4):422–424 PubMed
Kranias G, Krebs TP (2002) Advanced Coat’s disease successfully managed with vitreoretinal surgery. Eye (Lond) 16:500–501 CrossRef
Galliard MC, Mataftsi A, Balmer A, Houghton S, Munier FL (2014) Ranibizumab in the management of advanced coats disease stages 3B and 4. Retina 34:2275–2281 CrossRef
He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J (2010) Elevated vascular endothelial growth factor level in Coat’s disease and possible therapeutic role of bevacizumab. Graefes Arch ClinExp Ophthalmol 248:1519–1521 CrossRef
Zhang ZH, Yang XL, Jin HY et al(2016). Changes in retinal nerve fiber layer thickness after multiple injections of novel VEGF decoy receptor conbercept for various retinal diseases. Scientific Reports (6):38326
Sun ZH, Zhou HY, Lin B et al (2016) Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina 0:1–8
Bohm MR, Uhlig CE (2011) Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. G:mefes Arch Clin Exp Ophthalmol 249:1099–1101
Karatay M, Erdem Y, Koktekir E, Erkoc YS, Caydere M, Bayar MA (2012) The effect of bevacizumab on spinal epidural fibrosis in a postlaminectomy rat model. Turk Neurosurg 22:753–757 PubMed
- The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease
- Springer Berlin Heidelberg
Graefe's Archive for Clinical and Experimental Ophthalmology
Incorporating German Journal of Ophthalmology
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
Neu im Fachgebiet Augenheilkunde